A5091122881- Myasthenia Gravis and Thymoma
- Pituitary Gland Disorders and Treatments
- COVID-19 and healthcare impacts
- Cancer Immunotherapy and Biomarkers
- Neuroblastoma Research and Treatments
- Salivary Gland Tumors Diagnosis and Treatment
- Breast Cancer Treatment Studies
- SARS-CoV-2 and COVID-19 Research
- Cancer Treatment and Pharmacology
- Lung Cancer Diagnosis and Treatment
- Sarcoma Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Adrenal and Paraganglionic Tumors
- Ovarian cancer diagnosis and treatment
- Glioma Diagnosis and Treatment
- Adrenal Hormones and Disorders
- Cancer Risks and Factors
- Cutaneous Melanoma Detection and Management
- Cancer Cells and Metastasis
- Beetle Biology and Toxicology Studies
- Cancer Genomics and Diagnostics
- Autoimmune and Inflammatory Disorders Research
- Ultrasound in Clinical Applications
- Economic and Financial Impacts of Cancer
- Cardiac tumors and thrombi
Federico II University Hospital
2020-2025
University of Chicago
2025
University of Naples Federico II
2020-2024
Regione Campania
2023
Thymic carcinoma (TC) is a rare tumor with aggressive behavior. Chemotherapy carboplatin plus paclitaxel represents the treatment of choice for advanced disease. Antiangiogenic drugs, including ramucirumab, have shown activity in previously treated patients. The RELEVENT trial was designed to evaluate and safety ramucirumab chemotherapy as first-line TC.
Abstract Objectives Thymic epithelial tumors (TET) patients are at high risk of autoimmune and hypoimmune complications. Limited evidence is available on the potential immune-related inflammatory reactions induced by SARS-Cov-2 vaccine in this patient population. Methods In order to identify subjects higher for complications, we prospectively evaluated a panel serum biomarkers related inflammation (TNF-α, IL-1β, −6, −10, −12, −17A, IFN-α, β γ, MPO, MMP-9), vascular damage (E- P-selectin,...
Hormone receptor-positive (HR+)/HER2-negative (HER2-) early-stage breast cancers (EBC) are treated with adjuvant endocrine therapy (ET), chemotherapy (CT) reserved for high-risk cases. Obesity is linked to increased recurrence risk. The Oncotype DX® assay predicts prognosis and CT benefit. PRO BONO study evaluated DX test's impact on treatment decisions explored associations between genomic risk, tumor features, patient metabolic profiles. Patients HR+ /HER2-EBC undergoing testing were...
Ewing sarcoma (ES) represents the second most common malignant bone tumor in children and young adults. ES is not a frequent finding sites different from skeletal. Common of appearance are lower extremities, pelvis, paravertebral spaces head neck. Primary extraskeletal located anterior mediastinum very rare. These neoplasms should be discussed specialized contests with high volume patients treated. Here, we present an uncommon mediastinal mass challenging its characterization management.A...
Thymic epithelial tumors (TETs) are rare malignancies with heterogeneous clinical manifestations. The high frequency of autoimmune paraneoplastic disorders observed in such patients requires caution when using COVID-19 vaccines. Furthermore, TETs often associated severe immunodeficiency, making it difficult to predict vaccine immunization. Therefore, we aimed evaluate immune response TETs.We conducted a prospective study enrolling who underwent the SARS-Cov-2 mRNA full cycle (two doses plus...
Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the health systems worldwide. Data regarding impact of COVID-19 on cancer patients (CPs) undergoing or candidate for immune checkpoint inhibitors (ICIs) are lacking. We depicted practice and adaptations in management with solid tumors eligible receiving ICIs during pandemic, a special focus Campania region. Methods This survey (25 questions), promoted by young section SCITO (Società Campana di ImmunoTerapia...
Immunosuppression induced by anticancer therapy in a COVID-19-positive asymptomatic patient with cancer may have devastating effect and, eventually, be lethal. To identify cases among patients receiving active treatment, the Federico II University Hospital Naples performs rapid serological tests addition to hospital standard clinical triage for COVID-19 infection.From 6 17 April 2020, all candidates chemotherapy, radiotherapy or target/immunotherapy, if negative at on day scheduled received...
Background Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are highly effective. Nevertheless, immunocompromised participants were excluded from randomized controlled clinical trials. This study evaluates the efficacy and safety of Pfizer/BioNTech BNT162b2 (BNT162b2) vaccine in patients with breast gynecological cancer treated active anticancer therapy versus a control cohort healthy participants. Methods Immune responses to ( n = 44) or malignancy 6) on (28...
Background Thymic epithelial tumors (TETs) are frequently accompanied by Good Syndrome (GS), a rare immunodeficiency, characterized hypogammaglobulinemia and peripheral B cell lymphopenia. TETs can be also associated to other immunological disorders, both immunodeficiency autoimmunity. Methods In this study, we enrolled TET patients with GS address differences between or without autoimmune diseases (AD). We analyzed the immunophenotype from blood of these focusing on selected immune subsets...
Abstract Introduction Thymic epithelial tumors (TETs) are rare neoplasms often associated with immune-related disorders. Patients Good’s syndrome (GS), an adult-acquired TET-related immunodeficiency, at a high risk of mortality due to infectious diseases. This study aims examine COVID-19 occurrence and severity in TET patients, or without GS. Methods Clinical records patients referred the Regional Coordinating Center for Rare Tumors Campania Region were retrospectively collected. During...
Thymic epithelial tumors are rare malignancies with an incidence of 1.7 cases per million people year. They pose significant management challenges due to their association autoimmune disorders. In this case report, we present the 21-year history a patient diagnosed advanced B2/B3 thymoma and Good’s syndrome. The achieved complete durable response after receiving only two cycles immune checkpoint inhibitor Nivolumab. However, positive outcome was accompanied by development severe...